Skip to main content
. 2018 Mar 17;6(1):22. doi: 10.3390/diseases6010022

Table 1.

PCSK9 under development.

Drugs Type Status Study
Evolocumab Monoclonal Ab Approved Proficio Program
Alirocumab Monoclonal Ab Approved Odyssey Program
Bococizumab Monoclonal Ab Discontinued Spire Program
Inclisiran Silent RNA On approval Orion 1
LGT-209 Monoclonal Ab Discontinued -
RG7652 Monoclonal Ab Phase 2 Equator
ALN-PC RNAinhibitor Phase 1 ev/Preclinical sc -
Adnectin BMS-962476 modified binding protein Phase 1 -
EGF-A peptide synthetic peptide Preclinical -